Skip to main content
Equibles

UBS Group AG

Position in XTLB — Xtl Biopharmaceuticals Ltd

CIK 1610520 ZURICH, V8
Back to XTLB Full portfolio

Position in XTLB

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$341
-$551 QoQ
Shares Held
125
-34.6% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#2
of 2 holders
Holding Since
Sep 2020
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in XTLB Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,801 across 560 Biotechnology names. XTLB ranks #526 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in XTLB

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $341 125
2025-09-30 $892 763
2025-06-30 $1,523 1,336
2024-03-31 $19,540 6,954
2023-12-31 $54 54
2023-09-30 $108 120
2022-12-31 $363 300
2022-03-31 $1,924 812
2021-12-31 $426 154
2021-09-30 $12,693 2,898
2021-03-31 $11,734 3,524
2020-09-30 $1,968 1,036